GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Marksans Pharma Ltd

Marksans Pharma Q2 FY27 Investor Call Transcript Highlights Strong Growth, Profitability

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 13 Nov 2026, 02:23 PM IST  ·  BSE ID: b6369ff7-475d-4fc4-8fc2-e84faf874f2e
View Original BSE Filing (PDF)
💡
In Simple Terms
Marksans Pharma held an investor call detailing strong Q2 FY27 financial results, driven by revenue and profit growth across regions.
🤖 AI Summary
  • Marksans Pharma Q2 FY27 revenue from operations reached INR940 crores, a 30.5% year-on-year growth.
  • EBITDA for Q2 FY27 increased by 48.3% to INR214 crores, with an EBITDA margin of 22.8%.
  • Profit After Tax for Q2 FY27 stood at INR144 crores, marking a 44.8% year-on-year increase.
  • North America contributed INR421 crores (44.8% of revenue), while UK and Europe revenue grew 65% to INR405 crores.
  • Cash generated from operations for H1 FY27 was INR322 crores, compared to INR75 crores in H1 FY26.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Q2 FY27 Revenue from Operations
INR940 crores
30.5%
Q2 FY27 EBITDA
INR214 crores
48.3%
Q2 FY27 Profit After Tax
INR144 crores
44.8%
H1 FY27 Cash from Operations
INR322 crores
329.3%
Net Cash Position as of Sep-end
INR1,095 crores
North America Revenue Q2 FY27
INR421 crores
8.7%
U.K. and Europe Revenue Q2 FY27
INR405 crores
65%
Australia and New Zealand Revenue Q2 FY27
INR101 crores
64%
🏢 How This Affects the Company
📈
Business Impact
The company reported strong momentum across Europe, U.K., North America, and Australia/New Zealand, expanding its diversified business model. Growth was not dependent on a single geography or acquisition, with underlying business growth of approximately 25% excluding QliniQ.
💰
Financial Impact
Q2 FY27 profitability significantly improved, with EBITDA up 48.3% and PAT up 44.8%, expanding EBITDA margins by 274 basis points to 22.8%. Healthy cash generation for H1 FY27 of INR322 crores strengthened the net cash position to INR1,095 crores.
⚙️
Operational Impact
Investments in portfolio, commercial capabilities, and geographic expansions are translating into sustainable growth, particularly strengthening infrastructure in key European markets like QliniQ (Netherlands) and ABCnow/Marksans GmbH (Germany).
⚠️
Risk Impact
The Rest of World business was impacted by geopolitical disruptions, affecting the timing of certain shipments, indicating a regional operational risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this transcript.
👤
Who Is Affected
Shareholders are affected by the company's strong financial performance in Q2 and H1 FY27, including significant increases in revenue, profitability, and cash generation. Return on capital employed increased to 24.7% (trailing 12-month) and return on equity to 18.6%.
🔍
Management Signal
Management indicates a focus on deepening presence in existing markets, scaling new European platforms, expanding product portfolio, and evaluating selective acquisitions with strong financial positions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess sustained growth momentum across geographies.
Updates on European commercial infrastructure development and new product launches.
Further clarity on recovery of Rest of World business and shipment activities.
LOW RISK The geopolitical disruptions in the Rest of World business were noted as operational and timing-related, not a change in underlying opportunities.
💡 Investor Takeaway
Marksans Pharma reported Q2 FY27 revenue from operations of INR940 crores, a 30.5% YoY growth. Profit after tax increased 44.8% to INR144 crores, with EBITDA margin at 22.8%. H1 FY27 cash from operations was INR322 crores, increasing net cash to INR1,095 crores.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 revenue from operations grew 30.5% year-on-year to INR940 crores, reflecting broad-based performance.
  • EBITDA increased 48.3% to INR214 crores in Q2 FY27, with EBITDA margin expanding by 274 basis points to 22.8%.

⚠️ Concerns

  • Profit after tax declined sequentially to INR144 crores in Q2 FY27 from INR159 crores in Q1, partly due to higher depreciation and amortization.
  • The Rest of World business was impacted by ongoing geopolitical disruptions, affecting the timing of certain shipments during the quarter.
📅 Company Track Record
Marksans Pharma reported Q2 FY27 revenue grew 30.5% to Rs. 940.2 crore and PAT up 44.8%, as per the November 4, 2026 press release. The company previously reported H1 FY27 cash from operations up 901.93% and Q2 FY27 standalone revenue of Rs. 9,906.19 million.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Marksans Pharma's Q2 FY27 revenue from operations?
Marksans Pharma's revenue from operations for Q2 FY27 was INR940 crores, marking a 30.5% increase year-on-year.
What was Marksans Pharma's Profit After Tax for Q2 FY27?
The Profit After Tax for Marksans Pharma in Q2 FY27 was INR144 crores, representing a 44.8% year-on-year growth.
How much cash did Marksans Pharma generate from operations in H1 FY27?
Marksans Pharma generated INR322 crores cash from operations in H1 FY27, an increase from INR75 crores in the corresponding period last year.
What was the contribution of North America to Marksans Pharma's Q2 FY27 revenue?
North America contributed INR421 crores to Marksans Pharma's Q2 FY27 revenue, accounting for 44.8% of the total and growing 8.7% year-on-year.
What was Marksans Pharma's net cash position as of September end?
As of September end, Marksans Pharma's net cash position was INR1,095 crores, reflecting an increase of INR135 crores during the period.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.